Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis
Cancer presents a significant public health concern, particularly in the context of metastatic disease. Surgical removal of primary tumors, while essential, can inadvertently heighten the risk of metastasis. Thus, there is a critical need for innovative neoadjuvant therapies capable of curtailing me...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2429846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142219211243520 |
|---|---|
| author | Léa Bourguignon Roxann Hétu-Arbour Tania Charpentier Marilène Bolduc Denis Leclerc Krista M. Heinonen Alain Lamarre |
| author_facet | Léa Bourguignon Roxann Hétu-Arbour Tania Charpentier Marilène Bolduc Denis Leclerc Krista M. Heinonen Alain Lamarre |
| author_sort | Léa Bourguignon |
| collection | DOAJ |
| description | Cancer presents a significant public health concern, particularly in the context of metastatic disease. Surgical removal of primary tumors, while essential, can inadvertently heighten the risk of metastasis. Thus, there is a critical need for innovative neoadjuvant therapies capable of curtailing metastatic progression before or immediately following tumor resection. Addressing this imperative, the papaya mosaic virus nanoparticle (PapMV) has demonstrated potent immunostimulatory capabilities against both viruses and tumors, effectively hindering their proliferation. Our study reveals that PapMV exerts a protective effect against lung metastasis when administered systemically prior to tumor implantation or during the early stages of metastasis in various mouse models of cancer. This anti-tumor effect is initiated by the recruitment of myeloid cells in the lungs. These cells adopt a pro-inflammatory profile, secreting cytokines such as IFN-α, thus fostering a tumor microenvironment inhospitable to tumor progression. Crucially, this protective mechanism hinges on the presence of macrophages before treatment. TLR7 and IFN-I signaling pathways also play pivotal roles in this process. Furthermore, our findings demonstrate that PapMV triggers the activation of the bone marrow emergency response, which accounts for the influx of myeloid cells into the lungs. This study unveils a novel aspect of PapMV’s functionality. By bolstering the immune system, PapMV confers robust protection against metastasis at an early stage of disease progression. This discovery holds promise for therapeutic intervention, particularly as a preemptive measure prior to or just after surgical intervention. |
| format | Article |
| id | doaj-art-bb48637c0ce04e7b89fffb27e9da916e |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-bb48637c0ce04e7b89fffb27e9da916e2024-12-03T13:49:35ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2429846Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesisLéa Bourguignon0Roxann Hétu-Arbour1Tania Charpentier2Marilène Bolduc3Denis Leclerc4Krista M. Heinonen5Alain Lamarre6Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, CanadaCentre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, CanadaCentre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, CanadaDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, Quebec City, QC, CanadaDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, Quebec City, QC, CanadaCentre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, CanadaCentre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, CanadaCancer presents a significant public health concern, particularly in the context of metastatic disease. Surgical removal of primary tumors, while essential, can inadvertently heighten the risk of metastasis. Thus, there is a critical need for innovative neoadjuvant therapies capable of curtailing metastatic progression before or immediately following tumor resection. Addressing this imperative, the papaya mosaic virus nanoparticle (PapMV) has demonstrated potent immunostimulatory capabilities against both viruses and tumors, effectively hindering their proliferation. Our study reveals that PapMV exerts a protective effect against lung metastasis when administered systemically prior to tumor implantation or during the early stages of metastasis in various mouse models of cancer. This anti-tumor effect is initiated by the recruitment of myeloid cells in the lungs. These cells adopt a pro-inflammatory profile, secreting cytokines such as IFN-α, thus fostering a tumor microenvironment inhospitable to tumor progression. Crucially, this protective mechanism hinges on the presence of macrophages before treatment. TLR7 and IFN-I signaling pathways also play pivotal roles in this process. Furthermore, our findings demonstrate that PapMV triggers the activation of the bone marrow emergency response, which accounts for the influx of myeloid cells into the lungs. This study unveils a novel aspect of PapMV’s functionality. By bolstering the immune system, PapMV confers robust protection against metastasis at an early stage of disease progression. This discovery holds promise for therapeutic intervention, particularly as a preemptive measure prior to or just after surgical intervention.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2429846Cancer immunotherapyemergency myelopoiesismetastasis preventionneoadjuvant therapyvirus-based nanoparticle |
| spellingShingle | Léa Bourguignon Roxann Hétu-Arbour Tania Charpentier Marilène Bolduc Denis Leclerc Krista M. Heinonen Alain Lamarre Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis OncoImmunology Cancer immunotherapy emergency myelopoiesis metastasis prevention neoadjuvant therapy virus-based nanoparticle |
| title | Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis |
| title_full | Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis |
| title_fullStr | Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis |
| title_full_unstemmed | Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis |
| title_short | Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis |
| title_sort | systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis |
| topic | Cancer immunotherapy emergency myelopoiesis metastasis prevention neoadjuvant therapy virus-based nanoparticle |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2429846 |
| work_keys_str_mv | AT leabourguignon systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis AT roxannhetuarbour systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis AT taniacharpentier systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis AT marilenebolduc systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis AT denisleclerc systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis AT kristamheinonen systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis AT alainlamarre systemicadministrationofaviralnanoparticleneoadjuvantpreventslungmetastasisdevelopmentthroughemergencymyelopoiesis |